While having access to safe and efficient vaccines is essential for eradicating the COVID-19 pandemic, gaining marketing authorisation is a critical step in enabling and speeding this process. On December 2, 2020, the United Kingdom became the first country to approve the first COVID-19 vaccine. This commentary aims to provide a quick overview of the UK’s COVID-19 vaccine authorization process and compare it to that of the EU and the US. While the UK, EU, and US expedited the COVID-19 vaccine approval process, regulatory authorities did not appear to cut corners in their approval of the Pfizer COVID-19 vaccine, as evidenced by their decisions to switch emergency use authorization to full authorization in the US and to renew conditional/temporary use authorization in the EU and UK, respectively. There is an opportunity to conduct a thorough investigation into and comparison of the filed dossiers, as well as the robustness of the evaluation process for the approval of COVID-19 vaccines.
【저자키워드】 COVID-19 vaccines, EU, US, UK, marketing authorization, 【초록키워드】 Vaccine, COVID-19 vaccine, COVID-19 pandemic, Emergency use authorization, Pfizer, United Kingdom, Critical, Safe, approval, while, regulatory authority, country, authorisation, evidenced, 【제목키워드】 COVID-19 vaccine, Research, implication,